Holen Sie sich die Stockscreener-App
18.42
2.80%
-0.53
Schlusskurs vom Vortag:
$18.95
Offen:
$19.16
24-Stunden-Volumen:
258.62K
Relative Volume:
1.42
Marktkapitalisierung:
$986.03M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-25.59
EPS:
-0.7198
Netto-Cashflow:
-
1W Leistung:
-14.41%
1M Leistung:
-26.05%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$17.85
$19.16
1-Wochen-Bereich:
$17.85
$21.98
52-Wochen-Spanne:
$14.85
$28.38
Seaport Therapeutics Inc Stock (SPTX) Company Profile
Firmenname
Seaport Therapeutics Inc
Sektor
Branche
Telefon
617-807-4062
Adresse
6 TIDE STREET, BOSTON
Compare SPTX vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPTX
Seaport Therapeutics Inc
|
18.42 | 1.15B | 0 | 0 | 0 | -0.7198 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Seaport Therapeutics Inc Aktie (SPTX) Neueste Nachrichten
Seaport Therapeutics (NASDAQ:SPTX) Shares Gap UpWhat's Next? - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Shares Gap DownHere's What Happened - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Stock Price Down 6.3%Here's What Happened - MarketBeat
Seaport Therapeutics, Inc. (NASDAQ:SPTX) Stock Has Consensus Target Price of $38.57 - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Now Covered by Raymond James Financial - MarketBeat
Seaport Therapeutics, Inc. $SPTX Shares Newly Acquired by State Street Corp - MarketBeat
Seaport Therapeutics Price Target Announced at $46.00/Share by Raymond James - Moomoo
Raymond James initiates Seaport Therapeutics stock coverage with strong buy on depression drug potential - Investing.com South Africa
Raymond James Initiates Seaport Therapeutics at Strong Buy - marketscreener.com
Seaport Therapeutics, Inc. (SPTX) stock price, news, quote and history - Yahoo Finance UK
SPTX: Pivotal phase II trials for novel neuropsychiatric drugs advance, backed by robust funding - TradingView
Seaport Therapeutics at TD Cowen summit: pipeline gains momentum By Investing.com - Investing.com Canada
Seaport Therapeutics, Inc.(NasdaqGS: SPTX) added to S&P Global BMI Index - marketscreener.com
Seaport Therapeutics, Inc.(NasdaqGS:SPTX) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Seaport Therapeutics, Inc.(NasdaqGS: SPTX) added to Russell 3000E Growth Benchmark - marketscreener.com
Seaport Therapeutics to Participate in September Investor Conferences - Business Wire
The Manufacturers Life Insurance Company Acquires New Stake in Seaport Therapeutics, Inc. $SPTX - MarketBeat
Analysts Conflicted on These NA Names: SailPoint, Inc. (SAIL) and Seaport Therapeutics, Inc. (SPTX) - theglobeandmail.com
Analysts Offer Insights on NA Companies: Seaport Therapeutics, Inc. (SPTX), Navan, Inc. Class A (NAVN) and International Business Machines (IBM) - theglobeandmail.com
Seaport Therapeutics (NASDAQ:SPTX) Stock Price Up 4.6%Should You Buy? - MarketBeat
HC Wainwright Reaffirms Buy Rating for Seaport Therapeutics (NASDAQ:SPTX) - MarketBeat
symbol__ Stock Quote Price and Forecast - cnn.com
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers - biospace.com
Seaport Therapeutics at citigroup’s biopharma back to school summit 2026: platform push - Investing.com Canada
Seaport Therapeutics reports positive phase 1 trial results - investing.com
Seaport Therapeutics, Inc.Common Stock (Nasdaq:SPTX) Stock Quote - FinancialContent
Seaport Therapeutics reports positive phase 1 trial results By Investing.com - Investing.com Canada
PureTech Says Seaport Therapeutics Reports Positive Phase 1 Driving Trial Results for GlyphAllo - TradingView
RCSPureTech Health PLCPRTC's SPTX: New Positive Phase 1 GlyphAllo Data - TradingView
Seaport Therapeutics Says GlyphAllo Shows no Next-Morning Driving Impairment in Phase 1 Trial - marketscreener.com
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers - Business Wire
Citadel Advisors LLC Takes Position in Seaport Therapeutics, Inc. $SPTX - MarketBeat
Braidwell LP Takes $10.86 Million Position in Seaport Therapeutics, Inc. $SPTX - MarketBeat
Seaport Therapeutics, Inc. (NASDAQ:SPTX) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Alyeska Investment Group L.P. Makes New $1.63 Million Investment in Seaport Therapeutics, Inc. $SPTX - MarketBeat
Seaport Therapeutics, Inc. Common Stock (NASDAQ: SPTX) Stock Price, News & Analysis - kalkine.ca
Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference - BioSpace
Trv Gp Vi LLC Acquires New Shares in Seaport Therapeutics, Inc. $SPTX - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Stock Price Down 5.2%Here's Why - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Now Covered by Analysts at JonesTrading - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Sets New 52-Week HighHere's Why - MarketBeat
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO - 24/7 Wall St.
Seaport Therapeutics' (SPTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Seaport Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Selvaraju Reiterates Buy on Seaport, Citing Differentiated Neuropsychiatry Pipeline and Unchanged $50 Price Target - TipRanks
Seaport Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | SPTX | US81221K1088 - marketscreener.com
Seaport Therapeutics (NASDAQ:SPTX) Reaches New 52-Week HighHere's What Happened - MarketBeat
Seaport Therapeutics Inc. (SPTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PureTech Health (SPTX holder) discloses 31.2% Seaport Therapeutics stake - Stock Titan
Finanzdaten der Seaport Therapeutics Inc-Aktie (SPTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Seaport Therapeutics Inc-Aktie (SPTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ARCH Venture Partners XII, LLC | 10% Owner |
May 04 '26 |
Buy |
18.00 |
1,100,000 |
19,800,000 |
6,294,951 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):